21 May 2022 - Innovation is the lifeblood that has made America the most economically successful nation in the modern era. Biomedical innovation, however, is a costly and risky business. 

For example, only 5% of new cancer compounds make it to patients. Once breakthrough drugs or devices are approved as safe and effective for use by the FDA patients — especially those on public health programs — should have immediate access to them.

Unfortunately, this is far from the case.

Read The Hill article